Single-cell eQTL Mendelian randomization reveals the monocyte-associated PRKCB–CTSL axis as a candidate regulatory pathway and potential therapeutic target in rheumatoid arthritis - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Single-cell eQTL Mendelian randomization identifies a monocyte-linked PRKCB–CTSL pathway as a potential regulatory mechanism and therapeutic target in rheumatoid arthritis
Clinical Scorecard: Single-cell eQTL Mendelian randomization identifies a monocyte-linked PRKCB–CTSL pathway as a potential regulatory mechanism and therapeutic target in rheumatoid arthritis
At a Glance
Category
Detail
Condition
Rheumatoid arthritis (RA), a chronic autoimmune disorder marked by sustained synovial inflammation and progressive destruction of cartilage and bone.
Key Mechanisms
The study examines cell-type-specific genetic regulation of gene expression and its association with RA susceptibility, focusing on a monocyte-linked PRKCB–CTSL pathway identified in the title as a potential regulatory mechanism and therapeutic target.
Target Population
The analyses use RA GWAS summary statistics and cis-eQTL data from 17 immune-cell populations; no clinical patient cohort is described in the supplied excerpt.
Care Setting
Research context: integrated genetic, transcriptomic, computational, and in vitro analyses; the supplied excerpt does not describe a clinical care setting.
Key Highlights
The study integrated cell-type-specific cis-eQTL data from 17 immune-cell populations with RA GWAS summary statistics.
Mendelian randomization estimates assessed associations between genetically predicted expression of individual eGenes in defined immune-cell populations and RA susceptibility.
The broader analysis combined transcriptomic, WGCNA, machine-learning, single-cell, virtual perturbation, drug-screening, and in vitro approaches.
The article title identifies a monocyte-linked PRKCB–CTSL pathway as a potential regulatory mechanism and therapeutic target; the supplied excerpt does not provide detailed validation results.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
No patient-level prescribing or treatment cohort details are provided in the supplied excerpt.
The study examines candidate therapeutic targets and drug-screening analyses, but the supplied excerpt does not report a specific drug, dose, or prescribing recommendation.
Clinical Best Practices
Interpret the reported work as a research analysis of genetically prioritized RA-associated expression traits, not as a clinical diagnostic or treatment guideline.
For exposures with one qualifying instrument, the study used the Wald ratio; for exposures with multiple independent instruments, it used inverse-variance weighting and, when instrument counts allowed, MR-Egger and weighted-median analyses.
